{
    "organizations": [],
    "uuid": "0fef1cf1b09ea9e8018124443978d5ca8d6c82c0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-keytruda-monotherapy-met-primary-e/brief-keytruda-monotherapy-met-primary-endpoint-in-phase-3-study-significantly-improving-os-as-first-line-therapy-in-locally-advanced-or-metastatic-nsclc-patients-expressing-pd-l1-in-at-least-1-pct-of-tumor-cells-idUSFWN1RM0JT",
    "ord_in_thread": 0,
    "title": "BRIEF-Keytruda Monotherapy Met Primary Endpoint In Phase 3 Study, Significantly Improving OS As First-Line Therapy In Locally Advanced Or Metastatic NSCLC Patients Expressing PD-L1 In At Least 1 Pct Of Tumor Cells",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 9 (Reuters) - Merck & Co Inc:\n* KEYTRUDAÂ® (PEMBROLIZUMAB) MONOTHERAPY MET PRIMARY ENDPOINT IN PHASE 3 KEYNOTE-042 STUDY, SIGNIFICANTLY IMPROVING OS AS FIRST-LINE THERAPY IN LOCALLY ADVANCED OR METASTATIC NSCLC PATIENTS EXPRESSING PD-L1 IN AT LEAST 1 PERCENT OF TUMOR CELLS\n* SAFETY PROFILE OF KEYTRUDA IN PHASE 3 TRIAL WAS CONSISTENT\n* PHASE 3 KEYNOTE-042 TRIAL WILL CONTINUE TO EVALUATE PROGRESSION-FREE SURVIVAL (PFS), WHICH IS A SECONDARY ENDPOINT Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-09T18:56:00.000+03:00",
    "crawled": "2018-04-10T12:53:10.014+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "merck",
        "co",
        "inc",
        "pembrolizumab",
        "monotherapy",
        "met",
        "primary",
        "endpoint",
        "phase",
        "study",
        "significantly",
        "improving",
        "o",
        "therapy",
        "locally",
        "advanced",
        "metastatic",
        "nsclc",
        "patient",
        "expressing",
        "least",
        "percent",
        "tumor",
        "cell",
        "safety",
        "profile",
        "keytruda",
        "phase",
        "trial",
        "consistent",
        "phase",
        "trial",
        "continue",
        "evaluate",
        "survival",
        "pfs",
        "secondary",
        "endpoint",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}